news
Philips Sets Aside €288 Million to Settle US DOJ Sleep Recall
Philips Respironics agreed in principle to record a €288 million provision to resolve US Department of Justice investigations into its massive sleep therapy recall. The criminal and civil probes followed degraded sound-dampening foam in millions of CPAP and BiPAP devices. Final payment is scheduled for 2027 while Philips remains under a strict consent decree.
Philips Respironics agreed in principle to record a €288 million provision to resolve US Department of Justice investigations into its massive sleep therapy recall. The criminal and civil probes followed degraded sound-dampening foam in millions of CPAP and BiPAP devices. Final payment is scheduled for 2027 while Philips remains under a strict consent decree.
The architecture take
I remember talking to my uncle when the initial 2021 recall hit, watching him weigh breathing toxic foam against suffocating five times an hour. Five million recalled CPAP machines later, Philips is finally putting a €288 million price tag on its Department of Justice settlement. I used to think medical hardware got thorough vetting before landing on bedside tables, but this mess cured me of that illusion. Obstructive sleep apnea isn't an inconvenience; every airway collapse drives a spike in nocturnal cortisol, fragments slow-wave sleep, and locks the sympathetic nervous system into overdrive until morning. When the machine meant to protect your vascular tone starts off-gassing into your lungs, patients abandon therapy entirely. Compliance died. ResMed swallowed the market whole because people panicked, and I don't blame them. Settling cash in 2027 lets Philips clean its balance sheet, but patients now treat bedside sleep tech with the same cold skepticism usually reserved for off-brand supplements.